Ho Seong Kim1, Joon Young Choi1, Dong Wook Choi2, Ho Yeong Lim3, Joo Hee Lee1, Sun Pyo Hong1, Young Seok Cho1, Kyung-Han Lee1, Byung-Tae Kim1. 1. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710 Republic of Korea. 2. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710 Republic of Korea. 3. Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710 Republic of Korea.
Abstract
PURPOSE: To date, the prognostic value of (18)F-FDG PET/CT for patients with pancreatic neuroendocrine tumors (PNETs) has not been well characterized. We investigated the prognostic value of volumetric parameters using (18)F-FDG PET/CT in this patient population. METHODS: We retrospectively reviewed 20 cases of pathologically proven PNET in patients who had undergone pre-therapeutic (18)F-FDG PET/CT. PET parameters including maximum and average standardized uptake values (SUVmax, SUVave), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor were measured using a threshold SUV to determine the boundaries of the tumors. Univariate and multivariate survival analyses were performed with adjustments for PET parameters and other clinical values. RESULTS: The median clinical follow-up was 22.3 (range, 1.2-95.4) months. Cancer-related death occurred in 5 of 20 patients (25 %). Patients had clinical or pathological stages of I in seven patients, II in six patients, III in three patient, and IV in four patients. According to the WHO histological classification of subtypes, 3 patients exhibited well-differentiated PNETs, 13 patients had well-differentiated endocrine carcinomas, and 4 had poorly differentiatedendocrine carcinomas. Univariate analysis showed that tumor size (p = 0.028), AJCC stage (p = 0.009), T stage (p = 0.028), M stage (p = 0.029), treatment modality (p = 0.045), MTV (p = 0.003) and TLG (p = 0.027) were significant predictors of overall survival. On multivariate analysis, MTV (HR = 10.859, p = 0.031) was a significant independent predictor of overall survival along with the AJCC stage (HR = 11.556, p = 0.027). CONCLUSION: In patients with PNETs, the MTV of the primary tumor as measured by (18)F-FDG PET/CT along with the AJCC stage may be a significant independent prognostic factor for overall survival.
PURPOSE: To date, the prognostic value of (18)F-FDG PET/CT for patients with pancreatic neuroendocrine tumors (PNETs) has not been well characterized. We investigated the prognostic value of volumetric parameters using (18)F-FDG PET/CT in this patient population. METHODS: We retrospectively reviewed 20 cases of pathologically proven PNET in patients who had undergone pre-therapeutic (18)F-FDG PET/CT. PET parameters including maximum and average standardized uptake values (SUVmax, SUVave), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor were measured using a threshold SUV to determine the boundaries of the tumors. Univariate and multivariate survival analyses were performed with adjustments for PET parameters and other clinical values. RESULTS: The median clinical follow-up was 22.3 (range, 1.2-95.4) months. Cancer-related death occurred in 5 of 20 patients (25 %). Patients had clinical or pathological stages of I in seven patients, II in six patients, III in three patient, and IV in four patients. According to the WHO histological classification of subtypes, 3 patients exhibited well-differentiated PNETs, 13 patients had well-differentiated endocrine carcinomas, and 4 had poorly differentiatedendocrine carcinomas. Univariate analysis showed that tumor size (p = 0.028), AJCC stage (p = 0.009), T stage (p = 0.028), M stage (p = 0.029), treatment modality (p = 0.045), MTV (p = 0.003) and TLG (p = 0.027) were significant predictors of overall survival. On multivariate analysis, MTV (HR = 10.859, p = 0.031) was a significant independent predictor of overall survival along with the AJCC stage (HR = 11.556, p = 0.027). CONCLUSION: In patients with PNETs, the MTV of the primary tumor as measured by (18)F-FDG PET/CT along with the AJCC stage may be a significant independent prognostic factor for overall survival.
Authors: H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu Journal: J Nucl Med Date: 1997-12 Impact factor: 10.057
Authors: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Jeung Hye Han; Myung-Hwan Kim; Sung Hoon Moon; Soo Jung Park; Do Hyun Park; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee; Song Cheol Kim; Duck Jong Han Journal: Korean J Gastroenterol Date: 2009-02
Authors: Terry C Lairmore; Linda D Piersall; Mary K DeBenedetti; William G Dilley; Matthew G Mutch; Alison J Whelan; Barbara Zehnbauer Journal: Ann Surg Date: 2004-05 Impact factor: 12.969
Authors: Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim Journal: Ann Surg Oncol Date: 2009-10-14 Impact factor: 5.344
Authors: Esther Mena; Sara Sheikhbahaei; Mehdi Taghipour; Abhinav K Jha; Esther Vicente; Jennifer Xiao; Rathan M Subramaniam Journal: Clin Nucl Med Date: 2017-01 Impact factor: 7.794
Authors: Esben Andreas Carlsen; Camilla Bardram Johnbeck; Mathias Loft; Andreas Pfeifer; Peter Oturai; Seppo W Langer; Ulrich Knigge; Claes Nøhr Ladefoged; Andreas Kjaer Journal: J Nucl Med Date: 2021-02-26 Impact factor: 11.082
Authors: Hyun Ju Lee; Jong Jin Lee; Jeong Yeol Park; Jong Hyeok Kim; Yong Man Kim; Young Tak Kim; Joo Hyun Nam Journal: J Gynecol Oncol Date: 2017-07 Impact factor: 4.401